Congratulations to V Formation client and leading DMPK/ADME provider, XenoGesis, who has celebrated the official opening of its new laboratories and offices at BioCity Nottingham’s state-of-the-art Discovery Building.
With the support of grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Programme, XenoGesis has taken 5,500ft2 on the first floor of the Discovery Building following a move into the labs earlier this summer.
The new space provides an 83% increase on the laboratories and offices that XenoGesis previously occupied in the Innovation Building, where it had reached capacity. The company now employs 26 staff and has plans for significant future growth.
Around 60 guests and XenoGesis staff attended the official opening evening on 27th September including XenoGesis board members, Dr John Dixon and Glenn Crocker, who were guest speakers at the event. Guests enjoyed a drinks reception followed by presentations and a tour of the labs, with food provided by Posh Nosh.
Commenting on the official opening, XenoGesis Founder and MD, Richard Weaver said:
“It was fantastic to celebrate the official opening of our new labs and offices at the Discovery Building, which will provide us with the space we need to embark on our next phase of growth.
“We are thrilled with our new bespoke facilities which will provide an enhanced working environment for our growing team as well as accommodating our plans to expand our service offering for our clients, who we look forward to welcoming to XenoGesis.”
Founded in 2011, XenoGesis is an independent laboratory-based contract research organisation specialised in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction.
The core XenoGesis team has a proven track record of delivery in drug discovery. Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Since inception, XenoGesis has predicted the human PK and dose for 7 compounds that have entered clinical trials and the team are working with clients to refine the dose prediction for Phase 2.